ESTRELLA IMMUNOPHARMA INC (ESLA)

Company Profile

Estrella Immunopharma, Inc. operates as a pre-clinical stage biopharmaceutical company, which engages in the development of T-cell therapies with the capacity to address treatment and safety challenges for patients with blood cancers and solid tumors. The company is headquartered in Emeryville, California. The company went IPO on 2021-07-19. The firm is developing CD19 and CD22-targeted ARTEMIS T-cell therapies with the capacity to address treatment challenges for patients with blood cancers and solid tumors. Its lead product candidate, EB103, utilizes Eureka's ARTEMIS technology to target CD19, a protein expressed on the surface of almost all B-cell leukemias and lymphomas. The firm is also developing EB104, which also utilizes Eureka's ARTEMIS technology to target not only CD19, but also CD22, a protein that, like CD19, is expressed on the surface of most B-cell malignancies. The firm is also collaborating with Imugene Limited and its product candidate, CF33-CD19t an oncolytic virus (CF33-CD19t), to research the use of EB103 in conjunction with CF33-CD19t to treat solid tumors.

Company Info

ESTRELLA IMMUNOPHARMA INC

5858 Horton Street, Suite 370

Emeryville CALIFORNIA

P: 15103189098

Employees: 0

Website: https://www.estrellabio.com/